Literature DB >> 24072693

Hypoxia induces metalloproteinase-9 activation and human vascular smooth muscle cell migration through low-density lipoprotein receptor-related protein 1-mediated Pyk2 phosphorylation.

Elena Revuelta-López1, José Castellano, Santiago Roura, Carolina Gálvez-Montón, Laura Nasarre, Sonia Benitez, Antoni Bayes-Genis, Lina Badimon, Vicenta Llorente-Cortés.   

Abstract

OBJECTIVE: Hypoxia disturbs vascular function by promoting extracellular matrix remodeling. Extracellular matrix integrity and composition are modulated by metalloproteinases (MMPs). Our aim was to investigate the role of low-density lipoprotein receptor-related protein 1 (LRP1) in regulating MMP-9/MMP-2 activation and vascular smooth muscle cells (VSMCs) migration in response to hypoxia, and to elucidate the LRP1-signaling pathways involved in this process. APPROACH AND
RESULTS: Western blot analysis showed that hypoxia induced a sustained phosphorylation of proline-rich tyrosine kinase 2 concomitantly with LRP1 overexpression in human VSMCs (hVSMCs). Deletion of LRP1 using small-interfering RNA technology or treatment of hVSMCs with the Src family kinase inhibitor PP2 impaired hypoxia-induced phosphorylation of proline-rich tyrosine kinase 2 levels. Coimmunoprecipitation experiments showed that the higher amounts of phosphorylation of proline-rich tyrosine kinase 2/LRP1β immunoprecipitates in hypoxic hVSMCs were abolished in PP2-treated hVSMCs. Both LRP1 silencing and PP2 treatment were highly effective in the prevention of hypoxia-induced MMP-9 activation and hVSMC migration. Cellular subfractionation experiments revealed that PP2 effects may be caused by impairment of hypoxia-induced nuclear factor-κβ translocation to the nucleus. ELISA measurements showed that LRP1 silencing but not PP2 treatment increased interleukin-1β, interleukin-6, and monocyte chemoattractant protein-1 secretion by hypoxic hVSMCs.
CONCLUSIONS: Our findings determine a crucial role of LRP1-mediated Pyk2 phosphorylation on hypoxia-induced MMP-9 activation and hVSMC migration and therefore in hypoxia-induced vascular remodeling. Both LRP1 silencing and PP2 treatments also influence hypoxia-induced proinflammatory effects in hVSMCs. Therefore, further studies are required to establish therapeutical strategies that efficiently modulate vascular remodeling and inflammation associated with hypoxia-vascular diseases.

Entities:  

Keywords:  LRP1 protein, human; hypoxia; matrix metalloproteinase 1; protein tyrosine kinase Pyk2

Mesh:

Substances:

Year:  2013        PMID: 24072693     DOI: 10.1161/ATVBAHA.113.302323

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

1.  MMP9 inhibition increases autophagic flux in chronic heart failure.

Authors:  Shyam S Nandi; Kenichi Katsurada; Neeru M Sharma; Daniel R Anderson; Sushil K Mahata; Kaushik P Patel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-16       Impact factor: 4.733

2.  Omega-3 polyunsaturated fatty acids mitigate blood-brain barrier disruption after hypoxic-ischemic brain injury.

Authors:  Wenting Zhang; Hui Zhang; Hongfeng Mu; Wen Zhu; Xiaoyan Jiang; Xiaoming Hu; Yejie Shi; Rehana K Leak; Qiang Dong; Jun Chen; Yanqin Gao
Journal:  Neurobiol Dis       Date:  2016-02-24       Impact factor: 5.996

3.  Role of the LRP1-pPyk2-MMP9 pathway in hyperoxia-induced lung injury in neonatal rats.

Authors:  Ya-Fei Zheng; Hai-Yan Zhu; Wei Wang; Jing-Jing Hu; Tian-Ping Bao; Zhao-Fang Tian
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-12-15

4.  K Domain CR9 of Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1) Is Critical for Aggregated LDL-induced Foam Cell Formation from Human Vascular Smooth Muscle Cells.

Authors:  Paula Costales; Pablo Fuentes-Prior; Jose Castellano; Elena Revuelta-Lopez; Maria Ángeles Corral-Rodríguez; Laura Nasarre; Lina Badimon; Vicenta Llorente-Cortes
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

5.  A novel family of fluorescent hypoxia sensors reveal strong heterogeneity in tumor hypoxia at the cellular level.

Authors:  Raghu Erapaneedi; Vsevolod V Belousov; Michael Schäfers; Friedemann Kiefer
Journal:  EMBO J       Date:  2015-11-23       Impact factor: 11.598

6.  Thrombin Enhanced Matrix Metalloproteinase-9 Expression and Migration of SK-N-SH Cells via PAR-1, c-Src, PYK2, EGFR, Erk1/2 and AP-1.

Authors:  Chien-Chung Yang; Li-Der Hsiao; Chuen-Mao Yang; Chih-Chung Lin
Journal:  Mol Neurobiol       Date:  2016-05-16       Impact factor: 5.590

7.  Proline-rich tyrosine kinase 2 downregulates peroxisome proliferator-activated receptor gamma to promote hypoxia-induced pulmonary artery smooth muscle cell proliferation.

Authors:  Kaiser M Bijli; Bum-Yong Kang; Roy L Sutliff; C Michael Hart
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

8.  COMP-prohibitin 2 interaction maintains mitochondrial homeostasis and controls smooth muscle cell identity.

Authors:  Yiting Jia; Meili Wang; Chenfeng Mao; Fang Yu; Yingbao Wang; Rui Xiao; Changtao Jiang; Lemin Zheng; Qingbo Xu; Ming Zheng; Yi Fu; Qinghua Hu; Wei Kong
Journal:  Cell Death Dis       Date:  2018-06-04       Impact factor: 8.469

9.  Thymosin β4 protects against aortic aneurysm via endocytic regulation of growth factor signaling.

Authors:  Sonali Munshaw; Susann Bruche; Andia N Redpath; Alisha Jones; Jyoti Patel; Karina N Dubé; Regent Lee; Svenja S Hester; Rachel Davies; Giles Neal; Ashok Handa; Michael Sattler; Roman Fischer; Keith M Channon; Nicola Smart
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

10.  Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study.

Authors:  David de Gonzalo-Calvo; Laura López-Vilaró; Laura Nasarre; Maitane Perez-Olabarria; Tania Vázquez; Daniel Escuin; Lina Badimon; Agusti Barnadas; Enrique Lerma; Vicenta Llorente-Cortés
Journal:  BMC Cancer       Date:  2015-06-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.